(Q41704604)

English

Treatment of malignant ascites due to recurrent/refractory ovarian cancer: the use of interferon-α or interferon-α plus chemotherapy in vivo and in vitro

scientific article published on January 1, 1991

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

Treatment of malignant ascites due to recurrent/refractory ovarian cancer: the use of interferon-α or interferon-α plus chemotherapy in vivo and in vitro (English)

reason for preferred rank

most precise value

1 reference

10.1016/0277-5379(91)90024-8

https://api.crossref.org/works/10.1016/0277-5379(91)90024-8

6 December 2022

Treatment of malignant ascites due to recurrent/refractory ovarian cancer: the use of interferon-alpha or interferon-alpha plus chemotherapy in vivo and in vitro (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1835858

6 December 2022

1 reference

based on heuristic

inferred from title

1 reference

10.1016/0277-5379(91)90024-8

https://api.crossref.org/works/10.1016/0277-5379(91)90024-8

6 December 2022

author name string

W. R. Bezwoda

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1835858

6 December 2022

T. Golombick

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1835858

6 December 2022

R. Dansey

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1835858

6 December 2022

J. Keeping

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1835858

6 December 2022

language of work or name

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1835858

6 December 2022

publication date

1 January 1991

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

full work available at URL

https://api.elsevier.com/content/article/PII:0277537991900248?httpAccept=text/xml

1 reference

10.1016/0277-5379(91)90024-8

https://api.crossref.org/works/10.1016/0277-5379(91)90024-8

6 December 2022

https://api.elsevier.com/content/article/PII:0277537991900248?httpAccept=text/plain

1 reference

10.1016/0277-5379(91)90024-8

https://api.crossref.org/works/10.1016/0277-5379(91)90024-8

6 December 2022

European Journal of Cancer

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

27

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

1423-1429

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

Advanced ovarian adenocarcinoma. A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy

1

1 reference

10.1016/0277-5379(91)90024-8

https://api.crossref.org/works/10.1016/0277-5379(91)90024-8

6 December 2022

Long-term survival of advanced refractory ovarian carcinoma patients with small-volume disease treated with intraperitoneal chemotherapy

5

1 reference

10.1016/0277-5379(91)90024-8

https://api.crossref.org/works/10.1016/0277-5379(91)90024-8

6 December 2022

Intraperitoneal chemotherapy with high-dose cisplatin and cytosine arabinoside for refractory ovarian carcinoma and other malignancies principally involving the peritoneal cavity

6

1 reference

10.1016/0277-5379(91)90024-8

https://api.crossref.org/works/10.1016/0277-5379(91)90024-8

6 December 2022

Intraperitoneal carboplatin: favorable results in women with minimal residual ovarian cancer after cisplatin therapy

7

1 reference

10.1016/0277-5379(91)90024-8

https://api.crossref.org/works/10.1016/0277-5379(91)90024-8

6 December 2022

Use of interferon in the treatment of ovarian cancer as a single agent and in combination with cytotoxic drugs

11

1 reference

10.1016/0277-5379(91)90024-8

https://api.crossref.org/works/10.1016/0277-5379(91)90024-8

6 December 2022

Intraperitoneal recombinant interferon-alpha 2b for recurrent malignant ascites due to ovarian cancer

12

1 reference

10.1016/0277-5379(91)90024-8

https://api.crossref.org/works/10.1016/0277-5379(91)90024-8

6 December 2022

Establishment and characterization of two new human ovarian cancer cell lines UWOV1 and UWOV2 and a subline UWOV2 (Sf) growing in serum-free conditions: growth characteristics, biochemical, and cytogenetic studies

17

1 reference

10.1016/0277-5379(91)90024-8

https://api.crossref.org/works/10.1016/0277-5379(91)90024-8

6 December 2022

The proliferation and function of human mononuclear leukocytes and natural killer cells in serum-free medium

18

1 reference

10.1016/0277-5379(91)90024-8

https://api.crossref.org/works/10.1016/0277-5379(91)90024-8

6 December 2022

Phase I study and pharmacokinetics of intraperitoneal carboplatin

21

1 reference

10.1016/0277-5379(91)90024-8

https://api.crossref.org/works/10.1016/0277-5379(91)90024-8

6 December 2022

Quantitative studies on viral interference in suspended L cells. III. Effect of interfering viruses and interferon on the growth rate of cells

23

1 reference

10.1016/0277-5379(91)90024-8

https://api.crossref.org/works/10.1016/0277-5379(91)90024-8

6 December 2022

Mechanism of the Antitumour Effect of Interferon in Mice

25

1 reference

10.1016/0277-5379(91)90024-8

https://api.crossref.org/works/10.1016/0277-5379(91)90024-8

6 December 2022

Interferon and spontaneous cytotoxicity in man. V. Enhancement of spontaneous cytotoxicity in patients receiving human leukocyte interferon

27

1 reference

10.1016/0277-5379(91)90024-8

https://api.crossref.org/works/10.1016/0277-5379(91)90024-8

6 December 2022

Interferon and natural killer activity in multiple myeloma. Lack of correlation between interferon-induced enhancement of natural killer activity and clinical response to human interferon-alpha

29

1 reference

10.1016/0277-5379(91)90024-8

https://api.crossref.org/works/10.1016/0277-5379(91)90024-8

6 December 2022

Analysis of natural killer cell cytotoxicity of cancer patients treated with recombinant interferon

30

1 reference

10.1016/0277-5379(91)90024-8

https://api.crossref.org/works/10.1016/0277-5379(91)90024-8

6 December 2022

Low doses of interferon alpha result in more effective clinical natural killer cell activation

31

1 reference

10.1016/0277-5379(91)90024-8

https://api.crossref.org/works/10.1016/0277-5379(91)90024-8

6 December 2022

Identifiers

10.1016/0277-5379(91)90024-8

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

release_tfc4ooihfzextgbedqgtlm4ona

1 reference

https://api.fatcat.wiki/v0/release/tfc4ooihfzextgbedqgtlm4ona

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41704604&oldid=1836474474"